Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616460 | 0.88 | BRD4 (0.36) | BRD4ALDH1A1GAAPTGER3BMPR1B | |
| SCHEMBL19629951 | 0.82 | BMPR1B (0.37) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL19630004 | 0.79 | BRD4 (0.35) | BRD4ALDH1A1GAABMPR1BBMPR1A | |
| SCHEMBL5001527 | 0.75 | CHRM1 (0.39) | BRD4ALDH1A1GAAPTGER3BMPR1B | |
| SCHEMBL19615468 | 0.68 | BMPR1B (0.38) | ALDH1A1GAABMPR1BBMPR1ATGFBR1 | |
| SCHEMBL4997606 | 0.68 | ATAD2 (0.44) | BRD4ALDH1A1GAABMPR1BBMPR1A | |
| SCHEMBL31528058 | 0.67 | HSP90B1 (0.35) | — | |
| SCHEMBL5506028 | 0.66 | CHRM5 (0.48) | ALDH1A1GAA | |
| SCHEMBL11631002 | 0.66 | L3MBTL1 (0.40) | ALDH1A1GAA | |
| SCHEMBL10743515 | 0.66 | ALDH1A1 (0.41) | BRD4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | Bugworks Research, Inc. | 2019-09-26 | — | — | US | disclosed |
| WO-2017199265-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | ALPI, UROD, HLA-C | BRD4 4486/4885ALDH1A1 1285/4885GAA 127/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | BRD4 4649/4885ALDH1A1 568/4885GAA 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.